|
|
News Breaks | | | | October 5, 2012 | | 06:42 EDT |  | XNPT | XenoPort early Phase I data encouraging, says Leerink
Leerink views preliminary results from XenoPort's Phase I trial testing four different oral formulations of XP23829 as encouraging and reiterates an Outperform rating on the stock. The firm raised its price target for shares to $15 from $13. | |
|
News For XNPT From The Last 14 Days Check below for free stories on XNPT the last two weeks. |
|
|
| May 21, 2013 | | 07:53 EDT | | XNPT | XenoPort weakness creates buying opportunity, says Wells Fargo
 Subscribe for More Information | | | 06:23 EDT | | XNPT | XenoPort shares attractive at current levels, says Leerink
Subscribe for More Information | | | May 20, 2013 | | 16:22 EDT |  | XNPT | On The Fly: Closing Wrap
Subscribe for More Information | | | 13:06 EDT | | XNPT | On The Fly: Midday Wrap
Stocks on Wall Street were modestly higher at midday as the Dow and S&P seek to continue their march higher after closing last week at record levels. ECONOMIC EVENTS: In the U.S., the light domestic economic calendar included the Chicago Fed National Activity index, which slipped to -0.53 for April from its prior reading of -0.23. In Asia, the Hang Seng and Shanghai Composite both climbed after Chinese home prices were reported to have risen in April. COMPANY NEWS: Yahoo (YHOO) confirmed it is buying social media platform Tumblr for $1.1B, as widely reported over the weekend, and promised "not to screw it up" in its press release to announce the deal... Actavis (ACT) agreed to acquire Warner Chilcott (WCRX) in a stock-for-stock transaction valued at approximately $8.5B. The deal, which was approved by the boards of both companies, equates to a value of $20.08 per Warner Chilcott share based on Actavis' closing share price on Friday, the companies said. MAJOR MOVERS: Among the notable gainers were some other companies with M&A news: Acquity Group (AQ) shares more than doubled after Accenture (ACN) agreed to buy the company for $13.00 per American Depositary Share, and Pactera Technology (PACT) gained 31% after receiving a non-binding proposal from a Blackstone (BX) affiliate to be taken private for $7.50 per ADS. Among the noteworthy losers was XenoPort (XNPT), which fell 11% after one of its drugs failed in a Phase III trial for multiple sclerosis spasticity. Also lower were shares of Red Hat (RHT), which slid 4% following a downgrade to Market Perform at BMO Capital. INDICES: Near 1 pm ET, the Dow was up 13.67, or 0.09%, to 15,368.07; the Nasdaq was up 1.13, or 0.03%, to 3,500.10; and the S&P 500 was up 2.18, or 0.13%, to 1,669.65. | | | 12:47 EDT |  | XNPT | XenoPort downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information | | | 09:26 EDT |  | XNPT | On The Fly: Pre-market Movers
Subscribe for More Information | | | 06:36 EDT |  | XNPT | XenoPort to host conference call
Conference call to discuss AP Phase 3 clinical trial results and business updates will be held on May 20 at 8:30am. Webcast Link | | | 06:34 EDT | | XNPT | XenoPort reports top-line results for Phase 3 trial of Arbaclofen Placarbil
Subscribe for More Information | | | May 17, 2013 | | 08:38 EDT | | XNPT | XenoPort says shipments of Horizant have commenced
XenoPort announced that shipments of Horizant Extended-Release Tablets to its distributor in the United States have commenced. Depending on individual pharmacy ordering patterns, the product is anticipated to be generally available to patients in the first week of June. On May 1, XenoPort re-acquired from GlaxoSmithKline all commercialization rights to Horizant. Prior to the reacquisition of Horizant, GSK experienced manufacturing issues and delays that have resulted in a stockout of the product. | |
|
|
|
|
|
|
